



# Retraction: Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling

Shang Cai<sup>1</sup>, Qingqing Chen<sup>2</sup>, Yingying Xu<sup>1</sup>, Qianfeng Zhuang<sup>3</sup>, Shengjun Ji<sup>2</sup>

<sup>1</sup>Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China; <sup>2</sup>Department of Radiotherapy and Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China; <sup>3</sup>Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China

Correspondence to: Shengjun Ji, MD. Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, No. 16 Baita Road, Suzhou 215001, China. Email: happy168123@aliyun.com.

Submitted Jul 29, 2024. Accepted for publication Sep 10, 2024. Published online Oct 21, 2024.

doi: 10.21037/tcr-2024-6

View this article at: <https://dx.doi.org/10.21037/tcr-2024-6>

Retraction to: *Transl Cancer Res* 2020;9:1439-47.

The article (1) “Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling” (doi: 10.21037/tcr.2020.01.27) published in the Vol 9, No 3 (March 31, 2020) issue of *Translational Cancer Research* has been retracted at the request of all the authors. During a comprehensive review of the experimental data and accompanying figures, an unintentional error was identified in the duplication of certain panels within *Figure 7A*, attributed to a lapse during the assembly of the visual materials. This mistake does not affect the interpretation or conclusion of this article, as the relevant experiments were repeated, and replaceable figures from these repeated experiments can be found. Nonetheless, the authors have decided to retract this article considering the rigor and accuracy required in scientific research.

## Footnote

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-2024-6/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Cai S, Chen Q, Xu Y, et al. Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. *Transl Cancer Res* 2020;9:1439-47. Erratum in: *Transl Cancer Res* 2023;12:3220-1.

**Cite this article as:** Cai S, Chen Q, Xu Y, Zhuang Q, Ji S. Retraction: Atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. *Transl Cancer Res* 2024;13(10):5721-5722. doi: 10.21037/tcr-2024-6